Modulation of activation-loop phosphorylation by JAK inhibitors is binding mode dependent

Area of Science:

• Biochemistry
• Molecular Biology
• Pharmacology

Background:

• Janus kinase (JAK) inhibitors are crucial in treating inflammatory diseases and cancers.
• Current JAK inhibitors primarily use a Type I binding mode, targeting the ATP-binding pocket.
• Type I inhibitors can paradoxically increase JAK activation loop phosphorylation, despite inhibiting kinase function.

Purpose of the Study:

• To investigate the effects of Type II JAK inhibition on JAK activation loop phosphorylation.
• To elucidate the structural basis of JAK inhibition through X-ray crystallography.
• To determine factors influencing JAK inhibitor-induced activation loop phosphorylation.

Main Methods:

• X-ray crystallography to determine the structure of JAK2 kinase domain in an inactive conformation.
• Biochemical assays to assess activation loop phosphorylation in response to different JAK inhibitor types.
• Analysis of structural data to correlate inhibitor binding mode with kinase conformation.

Main Results:

• Type II JAK inhibition stabilizes an inactive kinase conformation, leading to decreased activation loop phosphorylation.
• The crystal structure of the JAK2 kinase domain in an inactive conformation was determined for the first time.
• JAK inhibitor-induced activation loop phosphorylation is dependent on receptor interaction and intact kinase/pseudokinase domains.

Conclusions:

• Type II JAK inhibitors offer a distinct mechanism by reducing activation loop phosphorylation, unlike Type I inhibitors.
• The conformation stabilized by a JAK inhibitor dictates whether activation loop hyperphosphorylation occurs.
• Understanding these distinct binding modes is critical for designing more effective JAK-targeted therapies.